Promising viral conjunctivitis treatment goes into Phase 2b trial

February 15, 2013

NovaBay Pharmaceuticals is conducting a global Phase 2b trial of its proprietary NVC-422, a new generation N-chlorotaurine-based molecule for treating viral conjunctivitis.

Emeryville, CA-NovaBay Pharmaceuticals Inc. is conducting a global Phase 2b trial of its proprietary NVC-422, a new generation N-chlorotaurine-based molecule for treating viral conjunctivitis.

The study, BAYnovation, is a multi-centered, randomized clinical study expected to enroll approximately 450 patients with confirmed adenoviral conjunctivitis throughout the United States, India, and Brazil. The study will be conducted in over 60 clinical trial sites worldwide, with 24 sites in India. BAYnovation is designed to evaluate NVC-422’s efficacy in eliminating the adenoviral infection, specifically treating the associated red eye, clearing the blurred vision, and reducing lingering effects left by the adenoviral conjunctivitis.

Enrollment is now underway in both U.S. and India, and is expected to be initiated in Brazil. Clinical data results are expected in the second half of 2013.